When intra-portal insulin levels are increased (e.g., obesity, Cushings syndrome, or due to treatment with glucocorticoids and glucagon-like peptide 1 receptor agonists) or decreased (e.g., malnutrition, anorexia nervosa and type 1 diabetes mellitus), these changes secondarily alter hepatic GH sensitivity resulting in a secondary association with discordant GH and IGF-I levels (e.g., high GH/low IGF-I levels or low GH/high IGF-I levels, respectively)
As a result, their cosmetics are not only effective but also gentle even on the most sensitive skin
Its lyophilized form and molecular stability support reproducible handling and precise biochemical analysis under controlled research conditions
Get Started Schedule a consultation with our medical team to learn if GHK/Epithalon dual-action therapy is right for your aesthetic and longevity goals
One (blue/green) for injecting, typically longer for intramuscular administration